GT-801

N/A

Report date: 2026/05/12 09:17:10

Base Information

Drug NameGT-801
Drug Alias NameGT801GT-801
ClassificationCell and gene therapy > Gene therapy > mRNABiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugate > Ab-tLNPCell and gene therapy > Gene therapy > LNP +[4] 
Mechanisms of ActionAnti-CD19
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsAutoimmune DiseasesAnemia, Hemolytic, AutoimmuneLymphoma, Non-Hodgkin +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companiesshenzhen Grit Biotechnology Co Ltd
China Registration ClassN/A

Develop Information

Active Companiesshenzhen Grit Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsAutoimmune DiseasesAnemia, Hemolytic, AutoimmuneLymphoma, Non-Hodgkin +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A